Daiichi Sankyo says mRNA COVID-19 Vaccine DS-5670 meets goal; files sNDA

7 September 2023

Japanese pharma major Daiichi Sankyo (TY0: 4568) today announced that the primary endpoint was achieved in a Phase III trial of a booster vaccination with DS-5670, an mRNA vaccine against the novel coronavirus infectious disease (COVID-19) being developed in Japan (in a booster vaccination trial).

Daiichi Sankyo also today revealed that it has submitted a supplemental New Drug Application (sNDA) to Japan’s Ministry of Health, Labor and Welfare (MHLW) for an omicron XBB.1.5-adapted mRNA vaccine (DS-5670) against the novel coronavirus infectious disease (COVID-19) for booster vaccination for individuals aged 12 years or older.

Japanese companies have been late to progress COVID-19 vaccines, and Daiichi only filed for its first approval of the vaccine at the start of this year. It was approved last month.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK